Brief: Sino Biopharmaceutical Says FDA Grants IND Approval For TQB6426 'GPC3 ADC' For Advanced Malignant Tumors
03/09/2026 16:51
BRIEF-Sino Biopharmaceutical Says FDA Grants IND Approval For TQB6426 'GPC3 ADC' For Advanced Malignant Tumors Sept 3 (Reuters) - Sino Biopharmaceutical Limited 1177.HK:
FDA GRANTS IND APPROVAL FOR TQB6426 'GPC3 ADC' FOR ADVANCED MALIGNANT TUMORS
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit